Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G13
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
KRAS mutation (239)
KRAS G12C (159)
KRAS G12D (64)
KRAS G12V (36)
KRAS wild-type (26)
KRAS G13D (22)
KRAS G12R (18)
RAS wild-type (17)
KRAS G12A (14)
KRAS G12 (10)
KRAS G12S (9)
KRAS mutation + STK11 mutation (8)
KRAS Q61H (7)
KRAS exon 2 mutation (7)
TP53 mutation + KRAS mutation (6)
KRAS G12C + STK11 mutation (5)
EGFR mutation + KRAS mutation (4)
KRAS A146 (4)
KRAS A59T (4)
KRAS Q61 (4)
KRAS A146T (3)
KRAS G12C + TP53 mutation (3)
KRAS G12D + STK11 mutation (3)
KRAS Y96D (3)
KRAS Y96S (3)
EGFR T790M + KRAS mutation (2)
EGFR V802I + KRAS mutation (2)
KEAP1 mutation + KRAS mutation (2)
KRAS A146V (2)
KRAS A59 (2)
KRAS A59S (2)
KRAS G12C + KEAP1 mutation (2)
KRAS G12D + KRAS G12V (2)
KRAS G13A (2)
KRAS G13C (2)
KRAS G13D + BRAF mutation (2)
KRAS K117 (2)
KRAS Q99L (2)
KRAS R68M (2)
KRAS exon 12 mutation (2)
KRAS exon 2 wild-type (2)
KRAS exon 3 mutation (2)
KRAS exon 4 mutation (2)
KRAS mutation + EGFR wild-type (2)
KRAS mutation + STK11 mutation + KEAP1 mutation (2)
KRAS mutation + TP53 wild-type (2)
PIK3CA mutation + KRAS mutation (2)
STK11 mutation + KEAP1 mutation + KRAS G12C (2)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + KRAS mutation (1)
APC mutation + KRAS mutation (1)
ARID1A mutation+ KRAS G12C (1)
BRAF V600E + KRAS G12R (1)
DICER1 A1690Gfs*9 + DICER1 E1813Q + KRAS G12L (1)
EGFR T790M + KRAS G12V (1)
KIR2DS4 mutation + KRAS mutation (1)
KRAS G12A + BRAF D549N (1)
KRAS G12C + ATM wild-type (1)
KRAS G12C + KRAS G12V (1)
KRAS G12C + SMARCA4 wild-type (1)
KRAS G12D + DNMT3A C559fsX (1)
KRAS G12V + BRAF V600E (1)
KRAS G12V + STK11 mutation (1)
KRAS G12V + TP53 mutation + APC mutation (1)
KRAS G60D (1)
KRAS G61 (1)
KRAS G61H + KRAS G12A (1)
KRAS N116H (1)
KRAS N116T (1)
KRAS Q22X (1)
KRAS Q61K (1)
KRAS Q61L (1)
KRAS S89P (1)
KRAS V12 (1)
KRAS codon 12 mutation + KRAS codon 13 mutation + EGFR mutation (1)
KRAS exon 13 mutation (1)
KRAS mutation + ATM mutation (1)
KRAS mutation + KEAP1 mutation (1)
KRAS mutation + SMARCA4 mutation (1)
KRAS mutation + STK11 deletion + KEAP1 deletion (1)
KRAS mutation + STK11 mutation + TP53 mutation (1)
KRAS mutation + U2AF1 mutation (1)
KRAS mutation + KMT2C mutation (1)
MAP2K1 G128D + KRAS mutation (1)
MET exon 14 mutation + KRAS G12A (1)
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
PIK3CA mutation + PTEN mutation + KRAS mutation (1)
PIK3CA wild-type + KRAS wild-type (1)
PTPN11 mutation + KRAS wild-type (1)
STK11 mutation + KEAP1 mutation + KRAS wild-type (1)
BRAF V600E + KRAS G12D (0)
CDKN2A mutation + CDKN2B mutation + KRAS mutation (0)
CDKN2A mutation + KRAS mutation (0)
KRAS A146P (0)
KRAS A59 (0)
KRAS G61H (0)
KRAS mutation + TP53 mutation (0)
KRAS mutation (239)
KRAS G12C (159)
KRAS G12D (64)
KRAS G12V (36)
KRAS wild-type (26)
KRAS G13D (22)
KRAS G12R (18)
RAS wild-type (17)
KRAS G12A (14)
KRAS G12 (10)
KRAS G12S (9)
KRAS mutation + STK11 mutation (8)
KRAS Q61H (7)
KRAS exon 2 mutation (7)
TP53 mutation + KRAS mutation (6)
KRAS G12C + STK11 mutation (5)
EGFR mutation + KRAS mutation (4)
KRAS A146 (4)
KRAS A59T (4)
KRAS Q61 (4)
KRAS A146T (3)
KRAS G12C + TP53 mutation (3)
KRAS G12D + STK11 mutation (3)
KRAS Y96D (3)
KRAS Y96S (3)
EGFR T790M + KRAS mutation (2)
EGFR V802I + KRAS mutation (2)
KEAP1 mutation + KRAS mutation (2)
KRAS A146V (2)
KRAS A59 (2)
KRAS A59S (2)
KRAS G12C + KEAP1 mutation (2)
KRAS G12D + KRAS G12V (2)
KRAS G13A (2)
KRAS G13C (2)
KRAS G13D + BRAF mutation (2)
KRAS K117 (2)
KRAS Q99L (2)
KRAS R68M (2)
KRAS exon 12 mutation (2)
KRAS exon 2 wild-type (2)
KRAS exon 3 mutation (2)
KRAS exon 4 mutation (2)
KRAS mutation + EGFR wild-type (2)
KRAS mutation + STK11 mutation + KEAP1 mutation (2)
KRAS mutation + TP53 wild-type (2)
PIK3CA mutation + KRAS mutation (2)
STK11 mutation + KEAP1 mutation + KRAS G12C (2)
ALK rearrangement + EGFR D761N + KRAS V14I (1)
ALK rearrangement + KRAS mutation (1)
APC mutation + KRAS mutation (1)
ARID1A mutation+ KRAS G12C (1)
BRAF V600E + KRAS G12R (1)
DICER1 A1690Gfs*9 + DICER1 E1813Q + KRAS G12L (1)
EGFR T790M + KRAS G12V (1)
KIR2DS4 mutation + KRAS mutation (1)
KRAS G12A + BRAF D549N (1)
KRAS G12C + ATM wild-type (1)
KRAS G12C + KRAS G12V (1)
KRAS G12C + SMARCA4 wild-type (1)
KRAS G12D + DNMT3A C559fsX (1)
KRAS G12V + BRAF V600E (1)
KRAS G12V + STK11 mutation (1)
KRAS G12V + TP53 mutation + APC mutation (1)
KRAS G60D (1)
KRAS G61 (1)
KRAS G61H + KRAS G12A (1)
KRAS N116H (1)
KRAS N116T (1)
KRAS Q22X (1)
KRAS Q61K (1)
KRAS Q61L (1)
KRAS S89P (1)
KRAS V12 (1)
KRAS codon 12 mutation + KRAS codon 13 mutation + EGFR mutation (1)
KRAS exon 13 mutation (1)
KRAS mutation + ATM mutation (1)
KRAS mutation + KEAP1 mutation (1)
KRAS mutation + SMARCA4 mutation (1)
KRAS mutation + STK11 deletion + KEAP1 deletion (1)
KRAS mutation + STK11 mutation + TP53 mutation (1)
KRAS mutation + U2AF1 mutation (1)
KRAS mutation + KMT2C mutation (1)
MAP2K1 G128D + KRAS mutation (1)
MET exon 14 mutation + KRAS G12A (1)
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
PIK3CA mutation + PTEN mutation + KRAS mutation (1)
PIK3CA wild-type + KRAS wild-type (1)
PTPN11 mutation + KRAS wild-type (1)
STK11 mutation + KEAP1 mutation + KRAS wild-type (1)
BRAF V600E + KRAS G12D (0)
CDKN2A mutation + CDKN2B mutation + KRAS mutation (0)
CDKN2A mutation + KRAS mutation (0)
KRAS A146P (0)
KRAS A59 (0)
KRAS G61H (0)
KRAS mutation + TP53 mutation (0)
›
Associations
(8)
News
Trials
Search handles
@BijoyTelivala
@GarridoLagunaMD
@HHorinouchi
@SyedAAhmad5
@pashtoonkasi
@weldeiry
Search handles
@BijoyTelivala
@GarridoLagunaMD
@HHorinouchi
@SyedAAhmad5
@pashtoonkasi
@weldeiry
Filter by
Latest
11ms
BI-2493 / BI-2865: non-covalent inhibitors, binding the inactive state of KRAS, blocked the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. @Boehringer #LCSM https://t.co/7m549MX20c (@HHorinouchi)
11 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12A • KRAS G12 • KRAS G13 • KRAS Q61H • KRAS A146V • KRAS G13C
|
BI-2493
1year
Very interesting! KRAS codon G12 mutations as a resistance biomarker on TAS102 for metastatic CRC? Pts with KRAS G13 codon mutations did better? @pashtoonkasi @GIcancerDoc @the_danielahn @IbrahimSahinMD1 @jonathanloree Comments? #CRCSM https://t.co/kRGjtmEmmp (@manjuggm)
1 year ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12 • KRAS G13
|
Lonsurf (trifluridine/tipiracil)
1year
Has anyone looked at kras G13 in pancreas cancer? @Aiims1742 @DrJashDatta @NbmerchantMD @AndrewMWaters @krushnacpatra https://t.co/vW4suPAZ5U (@SyedAAhmad5)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G13
over1year
Data presented by @tajiknia #AACRJCA22 shows MRTX1133 suppression of pERK at nM doses & synergies with 5-FU in CRC & pancreatic cancer cells with #KRAS G12D, G12V, & G13D. More studies needed before excluding non-G12D mutations from trials @BrownUCancer @BrownMedicine #eldeirylab https://t.co/DUlynIqYZH (@weldeiry)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12 • KRAS G13
|
5-fluorouracil • MRTX1133
over3years
Question that came up in our KRAS clinical trial group in @colontown. Does KRAS G13D mCRC respond differently to anti-EGFR abs? What papers show this? TY @pashtoonkasi @agrothey @doctorC369 (@manjuggm)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G13D • KRAS G13
over3years
I guess not all of us agree with this abstract conclusions. How can cfDNA guide treatment decisions in adjuvant setting in 2020? It simply can not unless one believes exploratory analysis, not even done with same test. Remind me story with Kras G13D an anti-EGFR in mCRC... (@GarridoLagunaMD)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G13D • KRAS G13
over3years
86 year old metastatic lung cancer with a malignant pleural effusion . Ecog Ps 0 PD L1 is 80 % Foundation 1 shows exon 14 met+ NF1+Nfkbia+ Tet2+Kras G13D+ RET What would be the first line treatment ? Pembro alone vs Capmatinib? @HosseinBorghaei @JackWestMD @PatelOncology (@BijoyTelivala)
over 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TET2 (Tet Methylcytosine Dioxygenase 2) • NFKBIA (NFKB Inhibitor Alpha 2)
|
KRAS G13D • KRAS G13
|
Keytruda (pembrolizumab) • Tabrecta (capmatinib)
almost4years
Since the 💧#ptDNA [Peritoneal Tumor DNA] can be tested using simple & cost effective methods (Droplet digital PCR (ddPCR) using a commercially available screening kits, in 👆🏾it was a KRAS G12/G13 kit), it could be paired with some of the available🩸#ctDNA to ⬆️sensitivity.💡 (@pashtoonkasi)
almost 4 years ago
HEOR
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12 • KRAS G13
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login